We were delighted to catch up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the use of epicutaneous immunotherapy for peanut allergy.
The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions:
- What are the pros and cons of oral immunotherapy and epicutaneous immunotherapy for peanut allergy? (0:13)
- Could you give us a brief overview of the clinical development of epicutaneous immunotherapy for peanut allergy? (3:37)
- What are the future directions of immunotherapy for peanut allergy? (4:41)
Disclosures: Philippe Bégin is the clinical trial investigator for DBV technology products.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
